The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Subscribe To Our Newsletter & Stay Updated
